Amisulpride for schizophrenia

Neto, Joaquim I Silveira da Mota; Soares, Bernardo; Lima, Maurí­cio Silva de

doi:10.1002/14651858.cd001357

Cited by 26 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few systematic reviews also indicated that the controlled trials of second-generation antipsychotics have mainly tested only a few kinds, including risperidone, olanzapine, quetiapine, loxapine, sertindole, aripiprazole, and amisulpride, and mostly compared them with placebo controls 43–50. The reviews concluded that second-generation antipsychotics had similar effects to FGAs in terms of reduction of positive symptoms.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Chien¹,

Yip²

2013

NDT

View full text Add to dashboard Cite

During the last three decades, an increasing understanding of the etiology, psychopathology, and clinical manifestations of schizophrenia spectrum disorders, in addition to the introduction of second-generation antipsychotics, has optimized the potential for recovery from the illness. Continued development of various models of psychosocial intervention promotes the goal of schizophrenia treatment from one of symptom control and social adaptation to an optimal restoration of functioning and/or recovery. However, it is still questionable whether these new treatment approaches can address the patients’ needs for treatment and services and contribute to better patient outcomes. This article provides an overview of different treatment approaches currently used in schizophrenia spectrum disorders to address complex health problems and a wide range of abnormalities and impairments resulting from the illness. There are different treatment strategies and targets for patients at different stages of the illness, ranging from prophylactic antipsychotics and cognitive–behavioral therapy in the premorbid stage to various psychosocial interventions in addition to antipsychotics for relapse prevention and rehabilitation in the later stages of the illness. The use of antipsychotics alone as the main treatment modality may be limited not only in being unable to tackle the frequently occurring negative symptoms and cognitive impairments but also in producing a wide variety of adverse effects to the body or organ functioning. Because of varied pharmacokinetics and treatment responsiveness across agents, the medication regimen should be determined on an individual basis to ensure an optimal effect in its long-term use. This review also highlights that the recent practice guidelines and standards have recommended that a combination of treatment modalities be adopted to meet the complex health needs of people with schizophrenia spectrum disorders. In view of the heterogeneity of the risk factors and the illness progression of individual patients, the use of multifaceted illness management programs consisting of different combinations of physical, psychological, and social interventions might be efficient and effective in improving recovery.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 99%

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Chien¹,

Yip²

2013

NDT

View full text Add to dashboard Cite

show abstract

“…10 At lower doses (50-300 mg/day), amisulpride enhances dopamine transmission by selectively antagonizing presynaptic autoreceptors, contributing to the drug's efficacy in addressing primarily negative symptoms, whereas at higher doses (400-800 mg/day), amisulpride antagonizes postsynaptic D2 and D3 receptors in the limbic system, which is predictive of potent antipsychotic activity. [10][11][12] Furthermore, amisulpride acts as a potent antagonist at the serotonin 5HT7 receptor, which is postulated to contribute to its antidepressant efficacy. 13,14 The limbic selectivity of amisulpride is associated with a low propensity for causing extrapyramidal side effects.…”

Section: Introductionmentioning

confidence: 99%

Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series

Poonia¹,

Sharaf²,

Procyshyn³

et al. 2022

CJHP

View full text Add to dashboard Cite

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Section: Resultsmentioning

confidence: 99%

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D R association rate and serotonin 5-HT antagonism, could contribute to this variation.

show abstract

Amisulpride for schizophrenia

Cited by 26 publications

References 61 publications

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Amisulpride Augmentation of Clozapine in Clozapine-Resistant Schizophrenia: A Case Series

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

Contact Info

Product

Resources

About